VasoStitch percutaneous access-and-closure system featured at ACC annual meeting

NewsGuard 100/100 Score

VasoStitch, a start-up medical technology company, announced today that its technology was featured at the annual scientific meeting of the American College of Cardiology (ACC) this week in Chicago. VasoStitch is developing a percutaneous access-and-closure system for the nonsurgical deployment of large-diameter transcatheter therapeutic devices, such as Transcatheter Aortic Valve Implants (TAVI) and Endovascular Aneurysm Repair (EVAR) devices. The VasoStitch system is designed to reduce procedural complexity and eliminate the need for an "open" surgical procedure.

“We now look forward to our First-in-Human milestone.”

The challenge with percutaneous catheter-based cardiac procedures is that a surgical cut-down is required for access and then closure. VasoStitch has developed two platform technologies designed to access and close percutaneous therapy sites without the need for open surgery, thus making catheter-based interventions simpler and more accessible.

"At this time, surgical means of arterial or cardiac access and closure for large-diameter, catheter-based interventions adds about 60 minutes to a lengthy and complicated procedure. Consequently, a device that can replicate the current 'gold standard' of surgical access and repair in a more rapid and facile fashion will reduce healthcare costs dramatically, enhance adoption of large-diameter cardiovascular and endovascular therapies, and improve the efficiency of patient management," said David W. J. Smith, President and CEO of VasoStitch. "We now look forward to our First-in-Human milestone."

The "unique benefits" of the VasoStitch technology include: (1) integrated access and closure; (2) optimal closure and healing; (3) ease of use; (4) universal size; and, (5) cost-effectivenes.

VasoStitch was founded by Amir Belson, MD. Dr. Belson previously founded NeoGuide Systems, a company that developed platform technology for minimally invasive surgical procedures and was acquired by Intuitive Surgical in 2009; more recently, Dr. Belson also has founded Emboline, Modular Surgical, RadGuard Medical, Thermocure, Vascular Pathways and ZipLine Medical.

Source:

 VasoStitch

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
NYU Langone Heart experts unveil breakthroughs at ACC 2024